What does PHARMACIE MARTIN-COSSE do?

PHARMACIE MARTIN-COSSE is a pharmacy in Andenne. Private Limited, started on 18 September 2001, 1 establishment.

What is the address of PHARMACIE MARTIN-COSSE?

The registered office of PHARMACIE MARTIN-COSSE is located at Rue de Leuze 386, 5300 Andenne.

Is PHARMACIE MARTIN-COSSE still active?

Yes. According to the CBE (28 September 2026) PHARMACIE MARTIN-COSSE is active, legal situation “Normale toestand”, started on 18 September 2001.

Is PHARMACIE MARTIN-COSSE registered on Peppol?

Yes, PHARMACIE MARTIN-COSSE is registered on the Peppol network with ID 0208:0475659492.

What is the enterprise number of PHARMACIE MARTIN-COSSE?

The enterprise number of PHARMACIE MARTIN-COSSE is BE0475659492.

When was PHARMACIE MARTIN-COSSE founded?

PHARMACIE MARTIN-COSSE was founded on 18 September 2001.

Who are the directors of PHARMACIE MARTIN-COSSE?

According to the 2025 annual accounts, the directors of PHARMACIE MARTIN-COSSE are: CAMELOU SRL.

Is PHARMACIE MARTIN-COSSE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 September 2001; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMACIE MARTIN-COSSE make in 2025?

PHARMACIE MARTIN-COSSE posted a profit after taxes of € 39,954 in financial year 2025.

What is the revenue of PHARMACIE MARTIN-COSSE?

As a small company, PHARMACIE MARTIN-COSSE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 243,949.

How much does an employee at PHARMACIE MARTIN-COSSE earn?

The average wage cost per full-time employee at PHARMACIE MARTIN-COSSE was € 49,500 in 2025: staff costs of € 118,752 for 2.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMACIE MARTIN-COSSE have?

According to the 2025 annual accounts, PHARMACIE MARTIN-COSSE has 2.4 full-time equivalents (FTE).

PHARMACIE MARTIN-COSSE (Private Limited) - Andenne

Dossier PHARMACIE MARTIN-COSSE, printed on 28 September 2026 from databakkes.be/en/0475659492/pharmacie-martin-cosse. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMACIE MARTIN-COSSE from Andenne, company number BE0475659492, closed financial year 2025 with a result of € 39,954 after tax. For that financial year PHARMACIE MARTIN-COSSE recorded a gross margin of € 243,949 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 59,457 to € 39,954. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Growing

€ 1.1 million

▲ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 39,954

▼ 33% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 34,918

▲ 127% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.1 million.

People and assets in 2025

Full-time equivalents

2.4

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 118,752

▼ 16% vs 2024

€ 49,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,093

▼ 29% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 263,738

▼ 26% vs 2024

€ 28,231 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 633,516

▲ 45% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 16,929

▼ 67% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 176,705 Gross margin 2022: € 176,705 First fiscal year in the series	€ 314,073 Gross margin 2023: € 314,073 ▲ 78% vs 2022 (€ 176,705) Favourable step	€ 316,464 Gross margin 2024: € 316,464 ▲ 1% vs 2023 (€ 314,073) Favourable step	€ 243,949 Gross margin 2025: € 243,949 ▼ 23% vs 2024 (€ 316,464) Unfavourable step	▼ 23%
Profit after taxes	€ 23,299 Profit after taxes 2022: € 23,299 First fiscal year in the series	€ 73,687 Profit after taxes 2023: € 73,687 ▲ 216% vs 2022 (€ 23,299) Favourable step	€ 59,457 Profit after taxes 2024: € 59,457 ▼ 19% vs 2023 (€ 73,687) Unfavourable step	€ 39,954 Profit after taxes 2025: € 39,954 ▼ 33% vs 2024 (€ 59,457) Unfavourable step	▼ 33%
Equity	€ 972,734 Equity 2022: € 972,734 First fiscal year in the series	€ 1,046,421 Equity 2023: € 1,046,421 ▲ 8% vs 2022 (€ 972,734) Favourable step	€ 1,105,878 Equity 2024: € 1,105,878 ▲ 6% vs 2023 (€ 1,046,421) Favourable step	€ 1,145,832 Equity 2025: € 1,145,832 ▲ 4% vs 2024 (€ 1,105,878) Favourable step	▲ 4%
Total debts	€ 1,017,972 Total debts 2022: € 1,017,972 First fiscal year in the series	€ 2,335,453 Total debts 2023: € 2,335,453 ▲ 129% vs 2022 (€ 1,017,972) Unfavourable step	€ 845,551 Total debts 2024: € 845,551 ▼ 64% vs 2023 (€ 2,335,453) Favourable step	€ 1,000,445 Total debts 2025: € 1,000,445 ▲ 18% vs 2024 (€ 845,551) Unfavourable step	▲ 18%
Cash	€ 59,254 Cash 2022: € 59,254 First fiscal year in the series	€ 16,228 Cash 2023: € 16,228 ▼ 73% vs 2022 (€ 59,254) Unfavourable step	€ 15,363 Cash 2024: € 15,363 ▼ 5% vs 2023 (€ 16,228) Unfavourable step	€ 34,918 Cash 2025: € 34,918 ▲ 127% vs 2024 (€ 15,363) Favourable step	▲ 127%
Land & buildings	€ 420,750 Land & buildings 2022: € 420,750 First fiscal year in the series	€ 403,390 Land & buildings 2023: € 403,390 ▼ 4% vs 2022 (€ 420,750) Unchanged	€ 391,710 Land & buildings 2024: € 391,710 ▼ 3% vs 2023 (€ 403,390) Unchanged	€ 367,642 Land & buildings 2025: € 367,642 ▼ 6% vs 2024 (€ 391,710) Unchanged	▼ 6%
Retained profit	€ 952,734 Retained profit 2022: € 952,734 First fiscal year in the series	€ 1,026,421 Retained profit 2023: € 1,026,421 ▲ 8% vs 2022 (€ 952,734) Favourable step	€ 1,085,878 Retained profit 2024: € 1,085,878 ▲ 6% vs 2023 (€ 1,026,421) Favourable step	€ 1,125,832 Retained profit 2025: € 1,125,832 ▲ 4% vs 2024 (€ 1,085,878) Favourable step	▲ 4%
Bank debt	€ 396,631 Bank debt 2022: € 396,631 First fiscal year in the series	€ 272,175 Bank debt 2023: € 272,175 ▼ 31% vs 2022 (€ 396,631) Favourable step	€ 357,988 Bank debt 2024: € 357,988 ▲ 32% vs 2023 (€ 272,175) Unfavourable step	€ 263,738 Bank debt 2025: € 263,738 ▼ 26% vs 2024 (€ 357,988) Favourable step	▼ 26%
Balance sheet total	€ 1,990,706 Balance sheet total 2022: € 1,990,706 First fiscal year in the series	€ 3,381,874 Balance sheet total 2023: € 3,381,874 ▲ 70% vs 2022 (€ 1,990,706) Unchanged	€ 1,951,428 Balance sheet total 2024: € 1,951,428 ▼ 42% vs 2023 (€ 3,381,874) Unchanged	€ 2,146,277 Balance sheet total 2025: € 2,146,277 ▲ 10% vs 2024 (€ 1,951,428) Unchanged	▲ 10%
Employees (FTE)	2 Employees (FTE) 2022: 2 First fiscal year in the series	2.3 Employees (FTE) 2023: 2.3 ▲ 0.3 vs 2022 (2) Unchanged	2.5 Employees (FTE) 2024: 2.5 ▲ 0.2 vs 2023 (2.3) Unchanged	2.4 Employees (FTE) 2025: 2.4 ▼ 0.1 vs 2024 (2.5) Unchanged	▼ 0.1

Key figures of PHARMACIE MARTIN-COSSE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACIE MARTIN-COSSE?

What happened at PHARMACIE MARTIN-COSSE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 29, 2026 New annual accounts for financial year 2025: profit of € 39,954 (▼ 33% vs 2024). Source: NBB ↗
2015 CAMELOU SRL became a director. NBB
Oct 15, 2001 New establishment in Andenne. KBO
Sep 18, 2001 Start of the company according to the CBE. KBO

In short

From € 23,299 profit in 2022 to € 39,954 profit in 2025.

Paid € 86,982 in corporate taxes since 2022.

Best year ever: 2023, with € 73,687 profit.

On average € 101,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMACIE MARTIN-COSSE? We notify you, reason included.

Follow PHARMACIE MARTIN-COSSE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit